Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-escalation and Expansion Study to Evaluate Safety, Pharmacodynamics and Preliminary Efficacy of VV169 in Patients With Relapsed or Refractory Multiple Myeloma

NCT07802717 is registered in ClinicalTrials.gov with Vyriad, Inc. as lead sponsor.

NCT NCT07802717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07802717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-escalation and Expansion Study to Evaluate Safety, Pharmacodynamics and Preliminary Efficacy of VV169 in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Vyriad, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 8, 2026
Completion date
August 31, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma refractory